drugset / Trial / NCT01288664

Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis

NCT01288664

Phase 3 Withdrawn Sun Yat-sen University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a pilot study to evaluate the efficacy and safety of Tacrolimus Sustained-release Capsules (ADVAGRAF) for the induction therapy of Lupus Nephritis (LN) (V, III +V, IV+V).

Timeline

Start
2011-01
Primary completion
2012-12
Completion
2012-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tacrolimus Small molecule 0.05 mg/kg
Subject Tacrolimus Small molecule 0.1 mg/kg

Indications